Ben Towne Center for Childhood Cancer Research
Back to... ➝
Donate Now
Vitanza Lab Menu
Back to... ➝
Donate Now

Publications

Selected publications by Dr. Vitanza and the Vitanza Lab. View a complete list of Vitanza’s publications on PubMed.

  • Vitanza NA, Wilson AL, Yokoyama JK, Johnson AJ, Huang W, Baxter BA, Meechan M, Koning RW, Reid AN, Gustafson JA, Biery MC, Myers C, Brown C, Gust J, Rawlings-Rhea S, Seidel K, Albert CM, Foster JB, Berens ME, Dun MD, Browd SR, Hauptman JS, Lee A, Ojemann JG, Crotty EE, Leary SES, Cole BL, Perez FA, Wright JN, Orentas RJ, Chour T, Newell EW, Whiteaker JR, Zhao L, Paulovich AG, Pinto N, Gust J, Gardner RA, Jensen MC, Park JR. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2023 Jan 9;13(1):114-131. doi: 10.1158/2159-8290.CD-22-0750.PMID: 36259971.
  • Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, Wein A, Brown C, Beebe A, Kong A, Kirkey D, Lee BM, Leary SES, Crotty EE, Hoeppner C, Holtzclaw S, Wilson AL, Gustafson JA, Foster JB, Iliff JJ, Goldstein HE, Browd SR, Lee A, Ojemann JG, Pinto N, Gust J, Gardner RA, Jensen MC, Hauptman JS, Park JR. Locoregional CAR T cells for children with CNS tumors: clinical procedure and catheter safety. Neoplasia. 2023 Jan 2;36:100870. doi: 10.1016/j.neo.2022.100870. Online ahead of print. PMID: 36599192
  • Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama J, Kunkle A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Locoregional HER2-specific CAR T cells for pediatric CNS tumors: preclinical spacer optimization to initial clinical experience. Nat Med.
  • Ravanpay AC, Gust J, Johnson AJ, Berger C, Rolczynski LS, Cecchini M, Chang CA, Hoglund VJ, Mukherjee R, Vitanza NA, Orentas RJ, Jensen MC. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 2019 Dec 17; 10(66):7080-7095. PMID: 31903167
  • Tam LT, Yeom KW, Wright JN, Jaju A, Radmanesh A, Han M, Toescu S, Maleki M, Chen E, Campion A, Lai HA, Eghbal AA, Oztekin O, Mankad K, Hargrave D, Jacques TS, Goetti R, Lober RM, Cheshier SH, Napel S, Mourad S, Aquilina K, Ho CY, Monje M, Vitanza NA*, Mattonen SA*. Neurooncol Adv. 2021 Mar 5;3(1):vdab042. [*co-last authors] PMID: 33977272
  • Biery MC, Noll A, Myers C, Morris SM, Winter CA, Parkiam F, Cole BL, Browd SR, Olson JM, Vitanza NA. A protocol for the generation of treatment-naïve biopsy-derived diffuse intrinsic pontine glioma and diffuse midline glioma models. J of Experi Neuro. J Exp Neurol. 2020 Dec;1(4):158-167. doi: 10.33696//Neurol.1.025. PMID: 33768215
  • Vitanza NA, Biery MC, Myers C, Ferguson E, Zhang Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Sarthy S, Morris SM, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JM. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. Neuro Oncol. 2020 Nov 1:noaa249. doi: 10.1093/neuonc/noaa249. Online ahead of print. PMID: 33130903
  • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogan RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA. Children with DIPG and other high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital Experience. J Neurooncol. 2020 Jun 16. doi: 10.1007/s11060-020-03558-w. Online ahead of print. PMID: 32556862
  • Lin GL, Wilsom, KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn M, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem, Geraghty AC, Ni L, Andreasson K, Vitanza NA, Warren K, Thomas C, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Transl. Med. 2019 Nov 20; 11(519). PMID: 31748226
  • Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Lui F, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017 May 8;31(5):635-652.e6. PMID: 28434841
  • Williams JR, Young CC, Vitanza NA, McGrath M, Feroze A, Hauptman J. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care. Neurosurg Focus. 2020 Jan 1; 48(1):E4. PMID: 31896081
  • Vitanza NA, Monje M. Diffuse Intrinsic Pontine Glioma: from diagnosis to next-generation clinical trials. Curr Treatment Options Neurol. 2019 Jul 10;21(8):37. PMID: 31290035
  • Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Vitanza NA, Leary SES, Crane CA. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy. Neuro Oncol. 2019 Jan 1;21(1):83-94. PMID: 30169876

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

 Accept All Cookies